Communiqués BioRestorative Therapies, Inc.

Actions

BRTX

US0906556065

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 31/05/2024			Varia. 5j.	Varia. 1 janv.
1,25 ^USD	+0,81 %		-3,10 %	-28,16 %

15/05	BioRestorative annonce la signature d'un accord d'approvisionnement exclusif de cinq ans avec Cartessa Aesthetics, LLC	CI
08/05	BioRestorative Therapies, Inc. renforce son programme métabolique préclinique avec un nouveau produit biologique à base d'exosomes ciblant l'obésité	CI

Communiqués

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

BioRestorative Therapies Announces Receipt of Nasdaq Non-Compliance Notice	25/05	AQ
BioRestorative Therapies : Non-Reliance on Previously Issued Financial Report - Form 8-K	24/05	PU
BioRestorative Therapies Provides First Quarter 2024 Business Update	14/05	AQ
BioRestorative Therapies Enhances Preclinical Metabolic Program with a Novel Exosome-Based Biologic Targeting Obesity	08/05	AQ
BioRestorative Therapies to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024	30/04	AQ
BioRestorative Therapies Announces Transformative Commercial Agreement with Cartessa, a Global Leader in Medical Aesthetics Technology	30/04	AQ
BioRestorative Therapies Announces FDA Clearance of Phase 2 BRTX-100 Clinical Study Protocol Amendment	16/04	AQ
BioRestorative Therapies Partners with Galen Patient Recruitment to Accelerate Completion of Enrollment in Phase 2 Trial of BRTX-100 in Chronic Lumbar Disc Disease	08/04	AQ
BioRestorative Therapies Announces Filing of Form S-1 Registration Statement to Register for Resale Common Stock Underlying Previously Issued Warrants	03/04	AQ
BioRestorative Therapies Announces Filing of 2023 Annual Report on Form 10-K	01/04	AQ
BioRestorative Therapies to Participate in the 36th Annual ROTH Conference	11/03	AQ
BioRestorative Therapies Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $8.1 Million Gross Proceeds Priced At-the-Market	06/02	AQ
BioRestorative Therapies Presents Preliminary Clinical Data from Phase 2 Study of BRTX-100 in Chronic Lumbar Disc Disease	05/02	AQ
BioRestorative Therapies to Present Preliminary BRTX-100 Clinical Data at the Orthopaedic Research Society (ORS) 2024 Annual Meeting	01/02	AQ
BioRestorative Therapies Receives a Notice of Allowance by the United States Patent and Trademark Office for a Patent Application Related to its Obesity Program	12/12	AQ
BioRestorative Therapies, Inc. to Participate at the ROTH MKM Healthcare Opportunities Conference October 12, 2023 in New York City	09/10/23	AQ
BioRestorative Therapies Enters into Supply Agreement with Evolutionary Biologics	12/09/23	AQ
BioRestorative Therapies Announces Activation of Northwell Health in the Company's Phase 2 Clinical Trial Targeting Chronic Lumbar Disc Disease	11/09/23	AQ
BioRestorative Therapies Announces Activation of Northwell Health in the Company's Phase 2 Clinical Trial Targeting Chronic Lumbar Disc Disease	08/09/23	AQ
BioRestorative Therapies Announces $2.1 Million Registered Direct Offering	11/07/23	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués BioRestorative Therapies, Inc.

Actions

BRTX

US0906556065

Communiqués

Filtres